Maturing
AI enterprise software
Mid-cap software and IT-services companies keep rising on product news and analyst support. Clarivate (CLVT) launched an IPOne integration with Anthropic's Claude on 11 November 2026, and B. Riley raised its Telos (TLS) target to $11 from $9 on 10 November 2026. Telos is up 72.1% over one month, but most other news is conference appearances, awards and insider sales, including a share sale by Grid Dynamics (GDYN) CEO Leonard Livschitz reported 13 November 2026. EPAM, Kyndryl, Procore, Vertex and PAR dropped out of the leaders, while Grid Dynamics, NCR Voyix (VYX) and Asure Software (ASUR) joined.
Research notes in this theme → Maturing
Consumer brands & retail
Restaurant, furniture and fashion names have rallied together. TD Cowen raised its Arhaus (ARHS) target to $16 on 9 November 2026 and Guggenheim raised its target to $17 on 10 November 2026, while Capri (CPRI) named Justin Boxford as its next CEO on 11 November 2026. The gains are starting to show cracks. Bob's Discount Furniture (BOBS) lowered its full-year gross margin outlook on 9 November 2026, a securities class action was filed against Portillo's (PTLO) on 12 November 2026, and The RealReal (REAL) CFO sold stock on 13 November 2026. Capri joined the group this week.
Research notes in this theme → Maturing
Cyclical industrials
Industrial equipment and infrastructure companies are rising while insiders buy. Columbus McKinnon (CMCO) president David Wilson bought shares, reported 12 November 2026, and FTAI Infrastructure (FIP) CEO Kenneth Nicholson bought $1.53 million of stock, reported 13 November 2026. There is little other company news: TrueBlue (TBI) and Hayward (HAYW) had no headlines, so the gains rest more on price than on new business developments. Herc Rentals (HRI) joined the group this week.
Research notes in this theme → Maturing
Defense & aerospace
Aerospace and defense-intelligence suppliers are rising on contract and earnings news. HawkEye 360 (HAWK) announced $135 million in new global contracts on 12 November 2026, and analysts raised their Firefly Aerospace (FLY) forecasts after better-than-expected third-quarter results, reported 11 November 2026. Analysts are adjusting rather than adding conviction: Jefferies kept Firefly at Buy but lowered its target to $30, and BTIG held StandardAero (SARO) at a $35 target. HawkEye 360 joined the group this week, and BETA Technologies (BETA) dropped out.
Research notes in this theme → Maturing
M&A & special situations
Each of these companies is being acquired or has signed a deal. Silence Therapeutics (SLN) still expects its Merck KGaA deal to close in the first quarter of 2027. Surgery Partners (SGRY) filed a merger agreement on 9 November 2026, Braze (BRZE) filed one on 20 October 2026, and ULBI answered a tender offer in a Schedule 14D-9 on 28 October 2026. Much of the move is already in the price: ULBI is up 157.4% and SLN up 112.1% over one month, and Mizuho downgraded Surgery Partners to Neutral on 11 November 2026. EVgo (EVGO) no longer fits the group after Stifel cut it to Hold with a $2.50 target on 12 November 2026.
Research notes in this theme → Maturing
Managed care & health services
Hospital operators and care providers are growing through deals and raised guidance. Ardent Health (ARDT) agreed to buy Boone Health for $47 million in cash on 12 November 2026, and Lumexa Imaging (LMRI) raised its 2026 adjusted EPS guidance to $0.86-$0.90 from $0.71-$0.77 on 10 November 2026. Analysts are raising targets without turning bullish: BofA kept Ardent at Underperform while raising its target to $14, and TD Cowen held Teladoc (TDOC) at Hold with an $8 target. Lumexa joined the group after its guidance raise.
Research notes in this theme → Maturing
Medtech, diagnostics & life-science tools
Mid-cap device makers have moved up on product launches and clinical news. OrthoPediatrics (KIDS) began the full commercial launch of its VerteGlide spinal system on 9 November 2026, and Axogen (AXGN) reported early clinical outcomes in prostate nerve reconstruction the same day. Prices are still rising, with Axogen up 57.0% and Glaukos (GKOS) up 48.4% over one month, but the rest of the news is conference appearances rather than new results. Vericel (VCEL) joined the group after Truist raised its target to $65 on 9 November 2026 and Stephens raised its target to $68 on 10 November 2026.
Research notes in this theme → Maturing
Oncology & immunology
Developers of cancer and immune-disease drugs are trading on fresh clinical and analyst news. Xencor (XNCR) reported initial plamotamab data on 9 November 2026, and Leerink upgraded enGene (ENGN) to Outperform on 13 November 2026. Analysts are split: HC Wainwright raised its Delcath (DCTH) target to $36 on 10 November 2026, while Morgan Stanley cut its Genmab (GMAB) target to $56 on 13 November 2026 and a Xencor insider sold more than $3 million of stock. Genmab and Oruka Therapeutics (ORKA) joined the group this week.
Research notes in this theme → Maturing · changed from accelerating
Travel & leisure
Low-cost airlines and a theme-park operator have rallied together. Airline stocks traded higher on 9 November 2026, Frontier (ULCC) opened first-class reservations on 10 November 2026, and H Partners, the fund of Six Flags (FUN) director Rehan Jaffer, bought 1.45 million shares at an average of $10.30, reported 11 November 2026. The run has met operational setbacks: a Frontier flight diverted after cabin flooding on 12 November 2026, and Frontier shares were hit by a nationwide FAA ground stop on 14 November 2026. Allegiant (ALGT) dropped out and Asure Software (ASUR) moved to the software group, while Six Flags and Volaris (VLRS) joined.
Research notes in this theme →